VRCA Stock Price, Verrica Pharmaceuticals Quote, Chart

Market Summary

USD6.79-0.06

Market Closed

-0.88%

VRCA Stock Price

View Fullscreen

VRCA RSI Chart

VRCA Valuation

Market Cap

290.6M

Price/Earnings (Trailing)

-4.34

Price/Sales (Trailing)

56.71

Price/Free Cashflow

-7.46

VRCA Price/Sales (Trailing)

VRCA Profitability

Return on Equity

-338.99%

Return on Assets

-82.1%

Free Cashflow Yield

-13.4%

VRCA Fundamentals

VRCA Revenue

Revenue (TTM)

5.1M

Rev. Growth (Yr)

2.8K%

Rev. Growth (Qtr)

-31.85%

VRCA Earnings

Earnings (TTM)

-67.0M

Earnings Growth (Yr)

-314.94%

Earnings Growth (Qtr)

0.76%

Breaking Down VRCA Revenue

Last 7 days

-2.1%

Last 30 days

36.7%

Last 90 days

25.7%

Trailing 12 Months

4.4%

How does VRCA drawdown profile look like?

VRCA Financial Health

Current Ratio

4.55

Debt/Equity

2.17

Debt/Cashflow

-0.9

VRCA Investor Care

Shares Dilution (1Y)

1.35%

Diluted EPS (TTM)

-1.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	8.1M	7.1M	6.1M	5.1M
2022	11.3M	10.5M	9.8M	9.0M
2021	0	0	0	12.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Verrica Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	hayes christopher g.	acquired	-	-	40,000	chief legal officer
Mar 15, 2024	goldenberg gary	acquired	-	-	40,000	chief medical officer
Mar 15, 2024	bonaccorso joe	acquired	-	-	40,000	chief commercial officer
Mar 15, 2024	kohler terry	acquired	-	-	40,000	chief financial officer
Mar 15, 2024	white ted	acquired	-	-	112,500	president and ceo
Dec 29, 2023	perceptive advisors llc	bought	838,204	7.24	115,774	-
Dec 28, 2023	perceptive advisors llc	bought	892,901	7.08	126,116	-
Dec 27, 2023	perceptive advisors llc	bought	574,027	7.2	79,726	-
Dec 26, 2023	perceptive advisors llc	bought	354,691	6.49	54,652	-
Dec 22, 2023	perceptive advisors llc	bought	1,667,500	6.67	250,000	-

Which funds bought or sold VRCA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	BML Capital Management, LLC	unchanged	-	-252,000	1,065,600	0.71%
Apr 23, 2024	Legacy Trust	unchanged	-	-26,250	111,000	0.03%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.18	-18,000	4,000	-%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-	-	-%
Apr 18, 2024	Miracle Mile Advisors, LLC	unchanged	-	-165,510	699,868	0.02%
Apr 18, 2024	SteelPeak Wealth, LLC	added	0.44	-188,718	816,582	0.04%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	88.00	88.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	2.79	4,464,920	9,231,260	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-53,834	-	-%

Are Funds Buying or Selling VRCA?

Are funds buying VRCA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VRCA

No. of Funds

Unveiling Verrica Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	perceptive advisors llc	16.9%	7,099,182	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	9.99%	6,583,332	SC 13G
Feb 14, 2023	perceptive advisors llc	12.3%	5,038,983	SC 13G/A
Jul 15, 2022	manning paul b	37.4%	15,389,481	SC 13D
Feb 14, 2022	manning paul b	38.6%	10,627,577	SC 13G/A
Feb 14, 2022	perceptive advisors llc	13.1%	3,610,412	SC 13G/A
Feb 11, 2022	orbimed advisors llc	0.00%	0	SC 13G/A
Jan 27, 2022	davidson matt	2.04%	560,731	SC 13G/A
Feb 17, 2021	perceptive advisors llc	13.2%	3,410,412	SC 13G/A
Feb 16, 2021	manning paul b	38.0%	9,837,747	SC 13G/A

Recent SEC filings of Verrica Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	DEFA14A	DEFA14A
Apr 19, 2024	DEF 14A	DEF 14A
Apr 19, 2024	ARS	ARS
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Feb 29, 2024	8-K	Current Report
Feb 29, 2024	10-K	Annual Report

Peers (Alternatives to Verrica Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Verrica Pharmaceuticals Inc News

Latest updates

Verrica Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)												(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	-31.8%	1,988	2,917	182	125	68.00	8,319	5,546	2,773	-	-	-	12,000
Operating Expenses	-6.4%	25,125	26,834	11,798	7,126	6,280	6,871	9,335	7,841	8,470	11,768	10,731	11,940
S&GA Expenses	-15.3%	16,995	20,054	5,937	4,319	3,189	3,925	5,173	5,118	5,113	8,005	7,284	6,578
R&D Expenses	-18.3%	5,320	6,510	5,725	2,739	3,029	2,780	3,943	2,445	3,357	3,763	3,447	5,362
Interest Expenses	39.1%	2,305	1,657	-	-	-28.50	81.00	1,066	1,082	1,098	1,092	1,077	1,028
Net Income	0.8%	-24,614	-24,802	-10,990	-6,589	-5,932	83.00	-10,168	-8,470	-9,540	-12,829	-11,775	-936
Net Income Margin	-65.1%	-13.07*	-7.92*	-3.31*	-2.81*	-2.71*	-2.87*	-3.90*	-3.79*	-2.92*	-	-	-
Free Cashflow	1.0%	-14,734	-14,876	-4,728	-4,601	-5,020	1,748	-7,335	-8,345	-8,935	-10,637	2,203	-11,096

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-16.0%	82.00	97.00	62.00	69.00	45.00	49.00	63.00	72.00	80.00	89.00	99.00	108	74.00	80.00	87.00	94.00	68.00	76.00	81.00	86.00	92.00
Current Assets	-15.5%	78.00	92.00	57.00	63.00	39.00	43.00	57.00	66.00	74.00	83.00	93.00	102	68.00	74.00	83.00	91.00	65.00	74.00	80.00	85.00	91.00
Cash Equivalents	-17.5%	70.00	84.00	55.00	60.00	34.00	32.00	45.00	50.00	16.00	20.00	25.00	44.00	11.00	17.00	49.00	54.00	9.00	11.00	20.00	24.00	10.00
Inventory	266.3%	1.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-70.4%	1.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	1.00	1.00	0.00
Liabilities	12.7%	62.00	55.00	7.00	4.00	5.00	4.00	47.00	46.00	48.00	48.00	47.00	46.00	41.00	41.00	39.00	38.00	3.00	4.00	4.00	3.00	2.00
Current Liabilities	49.7%	17.00	11.00	6.00	3.00	3.00	3.00	46.00	45.00	46.00	46.00	45.00	45.00	39.00	39.00	39.00	3.00	3.00	4.00	4.00	3.00	2.00
Short Term Borrowings	-	-	-	-	-	-	-	42.00	42.00	42.00	41.00	41.00	-	35.00	-	-	-	-	-	-	-	-
Long Term Debt	1.1%	43.00	42.00	-	-	-	-	-	-	-	-	-	-	-	-	-	34.00	-	-	-	-	-
Shareholder's Equity	-53.3%	20.00	42.00	55.00	65.00	40.00	45.00	16.00	25.00	33.00	41.00	52.00	62.00	33.00	39.00	48.00	57.00	65.00	72.00	77.00	83.00	89.00
Retained Earnings	-11.9%	-230	-205	-181	-170	-163	-157	-157	-147	-138	-129	-116	-104	-103	-90.90	-80.40	-71.01	-61.19	-53.55	-47.46	-40.46	-33.08
Additional Paid-In Capital	0.8%	250	248	236	235	203	202	174	173	172	170	169	167	137	131	129	128	127	125	124	123	123
Shares Outstanding	0.8%	42.00	42.00	42.00	42.00	41.00	32.00	28.00	28.00	28.00	28.00	28.00	26.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	152	-	-	-	32.00	-	-	-	186	-	-	-	173	-	-	-	181	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	2.1%	-14,507	-14,811	-4,669	-4,590	-4,954	1,825	-7,181	-8,340	-8,698	-10,598	2,499	-10,785	-6,099	-7,608	-8,594	-7,906	-8,213	-7,228	-5,050	-6,917	-6,903
Share Based Compensation	-78.5%	2,075	9,663	1,544	1,094	1,171	1,413	1,085	1,316	1,321	1,481	1,848	1,403	6,340	1,231	1,252	998	802	905	846	780	654
Cashflow From Investing	-249.2%	-227	-65.00	-59.00	-11.00	6,754	2,069	2,205	43,013	4,011	6,291	-22,135	10,835	-858	-24,126	3,130	18,274	6,650	-2,028	263	21,070	-21,146
Cashflow From Financing	-100.1%	-27.00	44,044	-84.00	30,280	-	-16,851	-1.00	-18.00	-3.00	43.00	241	33,365	445	-	-90.00	34,877	204	4.00	212	3.00	9.00

VRCA Income Statement

2023-12-31

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues [Abstract]
Total revenue	$ 5,124	$ 9,032
Operating expenses:
Selling, general and administrative	47,305	17,405
Research and development	20,295	12,198
Loss on disposal of assets	2,537	0
Cost of product revenue	289	0
Cost of collaboration revenue	457	725
Total operating expenses	70,883	30,328
Loss from operations	(65,759)	(21,296)
Other (expense) income :
Interest income	2,740	476
Interest expense	(3,962)	(2,172)
Loss on extinguishment of debt	0	(1,437)
Other expense	(14)	(58)
Total other expense, net	$ (1,236)	$ (3,191)
Net loss per share, basic	$ (1.48)	$ (0.72)
Net loss per share, diluted	$ (1.48)	$ (0.72)
Weighted-average common shares outstanding, basic	45,342,451	34,163,437
Weighted-average common shares outstanding, diluted	45,342,451	34,163,437
Net loss	$ (66,995)	$ (24,487)
Other comprehensive gain:
Unrealized gain on marketable securities	0	29
Comprehensive loss	(66,995)	(24,458)
Product [Member]
Revenues [Abstract]
Total revenue	4,658	0
Collaboration [Member]
Revenues [Abstract]
Total revenue	$ 466	$ 9,032

VRCA Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 69,547	$ 34,273
Accounts receivable	4,248	0
Collaboration revenue receivable	0	388
Unbilled collaboration revenue	168	99
Inventory	1,022	0
Prepaid expenses and other assets	2,545	4,355
Total current assets	77,530	39,115
Property and equipment, net	1,052	3,887
Operating lease right-of-use asset	1,158	1,443
Finance lease right-of-use asset	1,405	0
Other non-current assets	452	276
Total assets	81,597	44,721
Current liabilities:
Accounts payable	2,464	507
Accrued expenses and other current liabilities	13,860	2,655
Operating lease liability	324	297
Financing lease liability	376	0
Total current liabilities	17,024	3,459
Operating lease liability	910	1,229
Financing lease liability	1,026	0
Long term debt	42,874	0
Total liabilities	61,834	4,688
Commitments and Contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value; 200,000,000 authorized; 42,518,697 shares issued and 42,413,553 shares outstanding as of December 31, 2023 and 41,199,197 shares issued and 41,094,053 shares outstanding as of December 31, 2022	4	4
Treasury stock, at cost, 105,144 shares as of December 31, 2023 and 2022	0	0
Additional paid-in capital	250,207	203,482
Accumulated deficit	(230,448)	(163,453)
Total stockholders’ equity	19,763	40,033
Total liabilities and stockholders’ equity	$ 81,597	$ 44,721

About Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

CEO	Mr. Ted White
WEBSITE	verrica.com
INDUSTRY	Biotechnology
EMPLOYEES	22

Verrica Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Verrica Pharmaceuticals Inc? What does VRCA stand for in stocks?

VRCA is the stock ticker symbol of Verrica Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Verrica Pharmaceuticals Inc (VRCA)?

As of Tue Apr 23 2024, market cap of Verrica Pharmaceuticals Inc is 290.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VRCA stock?

You can check VRCA's fair value in chart for subscribers.

What is the fair value of VRCA stock?

You can check VRCA's fair value in chart for subscribers. The fair value of Verrica Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Verrica Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VRCA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Verrica Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether VRCA is over valued or under valued. Whether Verrica Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Verrica Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VRCA.

What is Verrica Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, VRCA's PE ratio (Price to Earnings) is -4.34 and Price to Sales (PS) ratio is 56.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VRCA PE ratio will change depending on the future growth rate expectations of investors.